nodes	percent_of_prediction	percent_of_DWPC	metapath
Tolazoline—ADRA2C—attention deficit hyperactivity disorder	0.588	0.701	CbGaD
Tolazoline—ADRA2A—attention deficit hyperactivity disorder	0.251	0.299	CbGaD
Tolazoline—Naphazoline—ADRA2C—attention deficit hyperactivity disorder	0.00134	0.214	CrCbGaD
Tolazoline—HRH2—cardiovascular system—attention deficit hyperactivity disorder	0.000819	0.109	CbGeAlD
Tolazoline—Pargyline—MAOA—attention deficit hyperactivity disorder	0.000706	0.112	CrCbGaD
Tolazoline—Naphazoline—ADRA2A—attention deficit hyperactivity disorder	0.000572	0.0911	CrCbGaD
Tolazoline—Methamphetamine—ADRA2C—attention deficit hyperactivity disorder	0.000538	0.0857	CrCbGaD
Tolazoline—HRH2—nervous system—attention deficit hyperactivity disorder	0.000526	0.07	CbGeAlD
Tolazoline—HRH2—central nervous system—attention deficit hyperactivity disorder	0.000506	0.0674	CbGeAlD
Tolazoline—ADRA1A—forebrain—attention deficit hyperactivity disorder	0.000475	0.0633	CbGeAlD
Tolazoline—HRH2—brain—attention deficit hyperactivity disorder	0.000402	0.0535	CbGeAlD
Tolazoline—ADRA1A—cardiovascular system—attention deficit hyperactivity disorder	0.000402	0.0535	CbGeAlD
Tolazoline—Phentermine—MAOA—attention deficit hyperactivity disorder	0.000381	0.0607	CrCbGaD
Tolazoline—HRH1—forebrain—attention deficit hyperactivity disorder	0.000368	0.049	CbGeAlD
Tolazoline—ADRA2A—forebrain—attention deficit hyperactivity disorder	0.000361	0.0481	CbGeAlD
Tolazoline—Phentermine—SLC6A3—attention deficit hyperactivity disorder	0.000329	0.0524	CrCbGaD
Tolazoline—Dextroamphetamine—SLC6A3—attention deficit hyperactivity disorder	0.000314	0.0499	CrCbGaD
Tolazoline—Phenelzine—MAOA—attention deficit hyperactivity disorder	0.000311	0.0495	CrCbGaD
Tolazoline—ADRA2C—midbrain—attention deficit hyperactivity disorder	0.000299	0.0398	CbGeAlD
Tolazoline—Methamphetamine—MAOA—attention deficit hyperactivity disorder	0.000272	0.0433	CrCbGaD
Tolazoline—ADRA1A—nervous system—attention deficit hyperactivity disorder	0.000258	0.0343	CbGeAlD
Tolazoline—Amphetamine—SLC6A3—attention deficit hyperactivity disorder	0.000253	0.0403	CrCbGaD
Tolazoline—ADRA1A—central nervous system—attention deficit hyperactivity disorder	0.000248	0.0331	CbGeAlD
Tolazoline—Phentermine—SLC6A4—attention deficit hyperactivity disorder	0.000246	0.0392	CrCbGaD
Tolazoline—ADRA2C—nervous system—attention deficit hyperactivity disorder	0.000246	0.0327	CbGeAlD
Tolazoline—ADRA1A—cerebellum—attention deficit hyperactivity disorder	0.000243	0.0323	CbGeAlD
Tolazoline—ADRA2A—midbrain—attention deficit hyperactivity disorder	0.000239	0.0318	CbGeAlD
Tolazoline—ADRA2C—central nervous system—attention deficit hyperactivity disorder	0.000237	0.0315	CbGeAlD
Tolazoline—Methamphetamine—SLC6A3—attention deficit hyperactivity disorder	0.000234	0.0373	CrCbGaD
Tolazoline—ADRA2C—cerebellum—attention deficit hyperactivity disorder	0.000231	0.0308	CbGeAlD
Tolazoline—Methamphetamine—ADRA2A—attention deficit hyperactivity disorder	0.00023	0.0366	CrCbGaD
Tolazoline—HRH1—nervous system—attention deficit hyperactivity disorder	0.0002	0.0266	CbGeAlD
Tolazoline—ADRA1A—brain—attention deficit hyperactivity disorder	0.000197	0.0263	CbGeAlD
Tolazoline—ADRA2A—nervous system—attention deficit hyperactivity disorder	0.000196	0.0261	CbGeAlD
Tolazoline—HRH1—central nervous system—attention deficit hyperactivity disorder	0.000192	0.0256	CbGeAlD
Tolazoline—Amphetamine—SLC6A4—attention deficit hyperactivity disorder	0.000189	0.0301	CrCbGaD
Tolazoline—ADRA2A—central nervous system—attention deficit hyperactivity disorder	0.000189	0.0251	CbGeAlD
Tolazoline—Amphetamine—DRD2—attention deficit hyperactivity disorder	0.000188	0.0299	CrCbGaD
Tolazoline—ADRA2C—brain—attention deficit hyperactivity disorder	0.000188	0.025	CbGeAlD
Tolazoline—ADRA2A—cerebellum—attention deficit hyperactivity disorder	0.000185	0.0246	CbGeAlD
Tolazoline—Methamphetamine—SLC6A4—attention deficit hyperactivity disorder	0.000175	0.0279	CrCbGaD
Tolazoline—HRH1—brain—attention deficit hyperactivity disorder	0.000153	0.0203	CbGeAlD
Tolazoline—ADRA2A—brain—attention deficit hyperactivity disorder	0.00015	0.02	CbGeAlD
Tolazoline—ADRA2C—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	6.5e-05	0.000442	CbGpPWpGaD
Tolazoline—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	6.5e-05	0.000441	CbGpPWpGaD
Tolazoline—HRH2—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	6.48e-05	0.00044	CbGpPWpGaD
Tolazoline—ADRA2C—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	6.48e-05	0.00044	CbGpPWpGaD
Tolazoline—ADRA2A—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	6.48e-05	0.00044	CbGpPWpGaD
Tolazoline—HRH2—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	6.46e-05	0.000438	CbGpPWpGaD
Tolazoline—ADRA2B—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	6.45e-05	0.000438	CbGpPWpGaD
Tolazoline—HRH2—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	6.35e-05	0.000431	CbGpPWpGaD
Tolazoline—HRH2—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	6.34e-05	0.000431	CbGpPWpGaD
Tolazoline—ADRA2B—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	6.32e-05	0.000429	CbGpPWpGaD
Tolazoline—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	6.28e-05	0.000427	CbGpPWpGaD
Tolazoline—ADRA2C—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	6.27e-05	0.000426	CbGpPWpGaD
Tolazoline—HRH2—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	6.27e-05	0.000426	CbGpPWpGaD
Tolazoline—HRH2—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	6.23e-05	0.000423	CbGpPWpGaD
Tolazoline—HRH1—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	6.21e-05	0.000422	CbGpPWpGaD
Tolazoline—ADRA2C—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	6.17e-05	0.000419	CbGpPWpGaD
Tolazoline—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—attention deficit hyperactivity disorder	6.16e-05	0.000419	CbGpPWpGaD
Tolazoline—ADRA1A—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	6.09e-05	0.000414	CbGpPWpGaD
Tolazoline—ADRA2C—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	6.09e-05	0.000414	CbGpPWpGaD
Tolazoline—ADRA2C—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	6.09e-05	0.000414	CbGpPWpGaD
Tolazoline—ADRA2B—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	6.08e-05	0.000413	CbGpPWpGaD
Tolazoline—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	6.05e-05	0.000411	CbGpPWpGaD
Tolazoline—HRH2—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	6.05e-05	0.000411	CbGpPWpGaD
Tolazoline—HRH1—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	5.91e-05	0.000402	CbGpPWpGaD
Tolazoline—ADRA2B—Hemostasis—ADRA2A—attention deficit hyperactivity disorder	5.9e-05	0.000401	CbGpPWpGaD
Tolazoline—ADRA2C—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	5.9e-05	0.000401	CbGpPWpGaD
Tolazoline—HRH2—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	5.86e-05	0.000398	CbGpPWpGaD
Tolazoline—HRH2—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	5.84e-05	0.000397	CbGpPWpGaD
Tolazoline—ADRA1A—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	5.8e-05	0.000394	CbGpPWpGaD
Tolazoline—HRH1—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	5.79e-05	0.000393	CbGpPWpGaD
Tolazoline—HRH1—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	5.77e-05	0.000392	CbGpPWpGaD
Tolazoline—HRH2—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	5.76e-05	0.000391	CbGpPWpGaD
Tolazoline—HRH2—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	5.69e-05	0.000387	CbGpPWpGaD
Tolazoline—ADRA1A—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	5.68e-05	0.000386	CbGpPWpGaD
Tolazoline—ADRA2B—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	5.68e-05	0.000386	CbGpPWpGaD
Tolazoline—ADRA2C—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	5.67e-05	0.000385	CbGpPWpGaD
Tolazoline—ADRA1A—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	5.66e-05	0.000385	CbGpPWpGaD
Tolazoline—ADRA2A—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	5.66e-05	0.000384	CbGpPWpGaD
Tolazoline—HRH1—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	5.59e-05	0.00038	CbGpPWpGaD
Tolazoline—ADRA2B—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	5.59e-05	0.00038	CbGpPWpGaD
Tolazoline—ADRA2C—Hemostasis—ADRA2A—attention deficit hyperactivity disorder	5.52e-05	0.000375	CbGpPWpGaD
Tolazoline—HRH1—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	5.49e-05	0.000373	CbGpPWpGaD
Tolazoline—ADRA1A—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	5.49e-05	0.000373	CbGpPWpGaD
Tolazoline—HRH1—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	5.43e-05	0.000369	CbGpPWpGaD
Tolazoline—HRH1—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	5.43e-05	0.000369	CbGpPWpGaD
Tolazoline—ADRA1A—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	5.39e-05	0.000366	CbGpPWpGaD
Tolazoline—ADRA2A—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	5.39e-05	0.000366	CbGpPWpGaD
Tolazoline—HRH1—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	5.37e-05	0.000365	CbGpPWpGaD
Tolazoline—ADRA1A—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	5.33e-05	0.000362	CbGpPWpGaD
Tolazoline—ADRA1A—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	5.33e-05	0.000362	CbGpPWpGaD
Tolazoline—ADRA2C—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	5.31e-05	0.00036	CbGpPWpGaD
Tolazoline—HRH2—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	5.3e-05	0.00036	CbGpPWpGaD
Tolazoline—ADRA2A—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	5.28e-05	0.000359	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	5.27e-05	0.000358	CbGpPWpGaD
Tolazoline—ADRA2A—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	5.26e-05	0.000357	CbGpPWpGaD
Tolazoline—HRH1—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	5.26e-05	0.000357	CbGpPWpGaD
Tolazoline—ADRA2C—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	5.22e-05	0.000355	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	5.16e-05	0.000351	CbGpPWpGaD
Tolazoline—ADRA2A—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	5.1e-05	0.000346	CbGpPWpGaD
Tolazoline—HRH1—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	5.06e-05	0.000343	CbGpPWpGaD
Tolazoline—ADRA1A—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	4.96e-05	0.000337	CbGpPWpGaD
Tolazoline—ADRA2A—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	4.95e-05	0.000336	CbGpPWpGaD
Tolazoline—ADRA2A—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	4.95e-05	0.000336	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	4.89e-05	0.000332	CbGpPWpGaD
Tolazoline—ADRA2B—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	4.82e-05	0.000328	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	4.79e-05	0.000326	CbGpPWpGaD
Tolazoline—HRH1—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	4.73e-05	0.000321	CbGpPWpGaD
Tolazoline—HRH1—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	4.65e-05	0.000316	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	4.64e-05	0.000315	CbGpPWpGaD
Tolazoline—ADRA2A—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	4.61e-05	0.000313	CbGpPWpGaD
Tolazoline—ADRA1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	4.56e-05	0.00031	CbGpPWpGaD
Tolazoline—ADRA2C—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	4.51e-05	0.000306	CbGpPWpGaD
Tolazoline—ADRA2B—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	4.44e-05	0.000301	CbGpPWpGaD
Tolazoline—HRH2—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	4.4e-05	0.000299	CbGpPWpGaD
Tolazoline—ADRA2B—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	4.38e-05	0.000298	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	4.31e-05	0.000293	CbGpPWpGaD
Tolazoline—ADRA2B—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	4.25e-05	0.000289	CbGpPWpGaD
Tolazoline—ADRA2A—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	4.24e-05	0.000288	CbGpPWpGaD
Tolazoline—ADRA2B—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	4.22e-05	0.000286	CbGpPWpGaD
Tolazoline—ADRA2C—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	4.14e-05	0.000281	CbGpPWpGaD
Tolazoline—ADRA2C—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	4.09e-05	0.000278	CbGpPWpGaD
Tolazoline—HRH2—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	4.09e-05	0.000278	CbGpPWpGaD
Tolazoline—HRH1—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	4.01e-05	0.000273	CbGpPWpGaD
Tolazoline—ADRA2C—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	3.97e-05	0.00027	CbGpPWpGaD
Tolazoline—ADRA1A—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	3.94e-05	0.000268	CbGpPWpGaD
Tolazoline—ADRA2C—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	3.94e-05	0.000268	CbGpPWpGaD
Tolazoline—ADRA2B—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	3.92e-05	0.000266	CbGpPWpGaD
Tolazoline—HRH2—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	3.85e-05	0.000261	CbGpPWpGaD
Tolazoline—ADRA2B—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	3.83e-05	0.00026	CbGpPWpGaD
Tolazoline—ADRA2B—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	3.81e-05	0.000259	CbGpPWpGaD
Tolazoline—ADRA2B—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	3.8e-05	0.000258	CbGpPWpGaD
Tolazoline—ADRA2B—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	3.73e-05	0.000254	CbGpPWpGaD
Tolazoline—ADRA2B—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	3.73e-05	0.000253	CbGpPWpGaD
Tolazoline—HRH2—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	3.71e-05	0.000252	CbGpPWpGaD
Tolazoline—HRH1—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	3.69e-05	0.000251	CbGpPWpGaD
Tolazoline—ADRA2B—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	3.69e-05	0.00025	CbGpPWpGaD
Tolazoline—ADRA2C—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	3.66e-05	0.000249	CbGpPWpGaD
Tolazoline—ADRA2B—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	3.66e-05	0.000249	CbGpPWpGaD
Tolazoline—ADRA2A—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	3.66e-05	0.000249	CbGpPWpGaD
Tolazoline—HRH1—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	3.65e-05	0.000248	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	3.62e-05	0.000246	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	3.58e-05	0.000243	CbGpPWpGaD
Tolazoline—ADRA2C—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	3.58e-05	0.000243	CbGpPWpGaD
Tolazoline—HRH2—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	3.58e-05	0.000243	CbGpPWpGaD
Tolazoline—ADRA2B—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	3.56e-05	0.000242	CbGpPWpGaD
Tolazoline—ADRA2C—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	3.55e-05	0.000241	CbGpPWpGaD
Tolazoline—HRH1—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	3.54e-05	0.000241	CbGpPWpGaD
Tolazoline—HRH1—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	3.51e-05	0.000238	CbGpPWpGaD
Tolazoline—ADRA2C—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	3.49e-05	0.000237	CbGpPWpGaD
Tolazoline—ADRA2C—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	3.49e-05	0.000237	CbGpPWpGaD
Tolazoline—ADRA1A—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	3.47e-05	0.000236	CbGpPWpGaD
Tolazoline—HRH2—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	3.46e-05	0.000235	CbGpPWpGaD
Tolazoline—ADRA2A—Metabolism—ADRA2C—attention deficit hyperactivity disorder	3.46e-05	0.000235	CbGpPWpGaD
Tolazoline—ADRA2B—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	3.45e-05	0.000234	CbGpPWpGaD
Tolazoline—ADRA1A—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	3.44e-05	0.000234	CbGpPWpGaD
Tolazoline—ADRA2C—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	3.44e-05	0.000234	CbGpPWpGaD
Tolazoline—ADRA2B—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	3.43e-05	0.000233	CbGpPWpGaD
Tolazoline—ADRA2C—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	3.42e-05	0.000232	CbGpPWpGaD
Tolazoline—HRH2—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	3.4e-05	0.000231	CbGpPWpGaD
Tolazoline—ADRA2B—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	3.39e-05	0.00023	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	3.37e-05	0.000229	CbGpPWpGaD
Tolazoline—HRH2—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	3.36e-05	0.000228	CbGpPWpGaD
Tolazoline—ADRA2B—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	3.35e-05	0.000227	CbGpPWpGaD
Tolazoline—ADRA2C—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	3.33e-05	0.000226	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	3.32e-05	0.000226	CbGpPWpGaD
Tolazoline—HRH1—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	3.26e-05	0.000222	CbGpPWpGaD
Tolazoline—ADRA2A—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	3.23e-05	0.000219	CbGpPWpGaD
Tolazoline—ADRA2C—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	3.22e-05	0.000219	CbGpPWpGaD
Tolazoline—ADRA2C—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	3.21e-05	0.000218	CbGpPWpGaD
Tolazoline—ADRA1A—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	3.2e-05	0.000217	CbGpPWpGaD
Tolazoline—ADRA2A—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	3.2e-05	0.000217	CbGpPWpGaD
Tolazoline—HRH1—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	3.19e-05	0.000216	CbGpPWpGaD
Tolazoline—HRH1—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	3.17e-05	0.000215	CbGpPWpGaD
Tolazoline—ADRA2C—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	3.17e-05	0.000215	CbGpPWpGaD
Tolazoline—HRH1—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	3.16e-05	0.000215	CbGpPWpGaD
Tolazoline—HRH2—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	3.13e-05	0.000213	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	3.13e-05	0.000212	CbGpPWpGaD
Tolazoline—ADRA2C—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	3.13e-05	0.000212	CbGpPWpGaD
Tolazoline—ADRA2B—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	3.12e-05	0.000212	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	3.11e-05	0.000211	CbGpPWpGaD
Tolazoline—HRH1—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	3.11e-05	0.000211	CbGpPWpGaD
Tolazoline—HRH1—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	3.11e-05	0.000211	CbGpPWpGaD
Tolazoline—ADRA1A—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	3.1e-05	0.000211	CbGpPWpGaD
Tolazoline—HRH1—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	3.07e-05	0.000208	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	3.05e-05	0.000207	CbGpPWpGaD
Tolazoline—ADRA1A—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	3.05e-05	0.000207	CbGpPWpGaD
Tolazoline—HRH1—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	3.05e-05	0.000207	CbGpPWpGaD
Tolazoline—ADRA1A—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	3.01e-05	0.000204	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	2.99e-05	0.000203	CbGpPWpGaD
Tolazoline—ADRA2A—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	2.97e-05	0.000202	CbGpPWpGaD
Tolazoline—HRH1—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	2.96e-05	0.000201	CbGpPWpGaD
Tolazoline—ADRA2C—Metabolism—TPH2—attention deficit hyperactivity disorder	2.94e-05	0.0002	CbGpPWpGaD
Tolazoline—ADRA2C—Metabolism—CACNB2—attention deficit hyperactivity disorder	2.94e-05	0.0002	CbGpPWpGaD
Tolazoline—ADRA2C—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	2.91e-05	0.000198	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	2.91e-05	0.000197	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	2.91e-05	0.000197	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	2.89e-05	0.000196	CbGpPWpGaD
Tolazoline—ADRA2C—Metabolism—DPYD—attention deficit hyperactivity disorder	2.89e-05	0.000196	CbGpPWpGaD
Tolazoline—ADRA2A—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	2.88e-05	0.000196	CbGpPWpGaD
Tolazoline—HRH1—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	2.87e-05	0.000195	CbGpPWpGaD
Tolazoline—HRH1—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	2.86e-05	0.000194	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	2.83e-05	0.000192	CbGpPWpGaD
Tolazoline—HRH1—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	2.82e-05	0.000192	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	2.82e-05	0.000191	CbGpPWpGaD
Tolazoline—ADRA1A—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	2.8e-05	0.00019	CbGpPWpGaD
Tolazoline—ADRA2A—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	2.8e-05	0.00019	CbGpPWpGaD
Tolazoline—HRH1—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	2.79e-05	0.000189	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	2.78e-05	0.000189	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	2.77e-05	0.000188	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	2.73e-05	0.000186	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	2.7e-05	0.000183	CbGpPWpGaD
Tolazoline—ADRA2C—Metabolism—CACNA1C—attention deficit hyperactivity disorder	2.69e-05	0.000183	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	2.62e-05	0.000178	CbGpPWpGaD
Tolazoline—ADRA2A—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	2.6e-05	0.000177	CbGpPWpGaD
Tolazoline—HRH1—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	2.59e-05	0.000176	CbGpPWpGaD
Tolazoline—ADRA2B—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	2.59e-05	0.000176	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	2.55e-05	0.000173	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	2.54e-05	0.000172	CbGpPWpGaD
Tolazoline—ADRA2C—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	2.42e-05	0.000164	CbGpPWpGaD
Tolazoline—ADRA2B—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	2.4e-05	0.000163	CbGpPWpGaD
Tolazoline—ADRA2A—Metabolism—TPH2—attention deficit hyperactivity disorder	2.39e-05	0.000162	CbGpPWpGaD
Tolazoline—ADRA2A—Metabolism—CACNB2—attention deficit hyperactivity disorder	2.39e-05	0.000162	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	2.37e-05	0.000161	CbGpPWpGaD
Tolazoline—ADRA2C—Metabolism—SNAP25—attention deficit hyperactivity disorder	2.35e-05	0.00016	CbGpPWpGaD
Tolazoline—ADRA2A—Metabolism—DPYD—attention deficit hyperactivity disorder	2.35e-05	0.000159	CbGpPWpGaD
Tolazoline—ADRA2B—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	2.26e-05	0.000154	CbGpPWpGaD
Tolazoline—ADRA2C—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	2.25e-05	0.000153	CbGpPWpGaD
Tolazoline—ADRA2C—Metabolism—ADRA2A—attention deficit hyperactivity disorder	2.24e-05	0.000152	CbGpPWpGaD
Tolazoline—HRH2—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	2.19e-05	0.000149	CbGpPWpGaD
Tolazoline—ADRA2B—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	2.18e-05	0.000148	CbGpPWpGaD
Tolazoline—ADRA2A—Metabolism—CACNA1C—attention deficit hyperactivity disorder	2.18e-05	0.000148	CbGpPWpGaD
Tolazoline—HRH1—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	2.15e-05	0.000146	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	2.11e-05	0.000144	CbGpPWpGaD
Tolazoline—ADRA2C—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	2.11e-05	0.000144	CbGpPWpGaD
Tolazoline—ADRA2B—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	2.1e-05	0.000143	CbGpPWpGaD
Tolazoline—ADRA2C—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	2.04e-05	0.000139	CbGpPWpGaD
Tolazoline—ADRA2B—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	2.04e-05	0.000138	CbGpPWpGaD
Tolazoline—ADRA2B—Hemostasis—EP300—attention deficit hyperactivity disorder	2.02e-05	0.000137	CbGpPWpGaD
Tolazoline—ADRA2B—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	2e-05	0.000136	CbGpPWpGaD
Tolazoline—HRH1—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	2e-05	0.000136	CbGpPWpGaD
Tolazoline—ADRA2B—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	1.98e-05	0.000134	CbGpPWpGaD
Tolazoline—ADRA2C—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	1.96e-05	0.000133	CbGpPWpGaD
Tolazoline—ADRA1A—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	1.96e-05	0.000133	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	1.96e-05	0.000133	CbGpPWpGaD
Tolazoline—ADRA2A—Metabolism—SNAP25—attention deficit hyperactivity disorder	1.91e-05	0.00013	CbGpPWpGaD
Tolazoline—ADRA2C—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	1.9e-05	0.000129	CbGpPWpGaD
Tolazoline—ADRA2C—Hemostasis—EP300—attention deficit hyperactivity disorder	1.88e-05	0.000128	CbGpPWpGaD
Tolazoline—HRH1—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	1.88e-05	0.000128	CbGpPWpGaD
Tolazoline—ADRA2C—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	1.87e-05	0.000127	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	1.85e-05	0.000125	CbGpPWpGaD
Tolazoline—ADRA2C—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	1.85e-05	0.000125	CbGpPWpGaD
Tolazoline—ADRA2B—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.84e-05	0.000125	CbGpPWpGaD
Tolazoline—ADRA2A—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	1.82e-05	0.000124	CbGpPWpGaD
Tolazoline—HRH1—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	1.82e-05	0.000123	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	1.78e-05	0.000121	CbGpPWpGaD
Tolazoline—ADRA2C—Metabolism—COMT—attention deficit hyperactivity disorder	1.78e-05	0.000121	CbGpPWpGaD
Tolazoline—ADRA2C—Metabolism—MAOA—attention deficit hyperactivity disorder	1.77e-05	0.00012	CbGpPWpGaD
Tolazoline—HRH1—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	1.75e-05	0.000119	CbGpPWpGaD
Tolazoline—ADRA2C—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.72e-05	0.000117	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	1.72e-05	0.000117	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	1.72e-05	0.000117	CbGpPWpGaD
Tolazoline—HRH1—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	1.69e-05	0.000115	CbGpPWpGaD
Tolazoline—HRH1—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	1.67e-05	0.000113	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	1.66e-05	0.000113	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	1.66e-05	0.000113	CbGpPWpGaD
Tolazoline—HRH1—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	1.65e-05	0.000112	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	1.63e-05	0.000111	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	1.61e-05	0.00011	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	1.6e-05	0.000108	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	1.55e-05	0.000105	CbGpPWpGaD
Tolazoline—HRH1—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.53e-05	0.000104	CbGpPWpGaD
Tolazoline—ADRA2A—Hemostasis—EP300—attention deficit hyperactivity disorder	1.53e-05	0.000104	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.5e-05	0.000102	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	1.5e-05	0.000102	CbGpPWpGaD
Tolazoline—ADRA2A—Metabolism—COMT—attention deficit hyperactivity disorder	1.45e-05	9.82e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Metabolism—MAOA—attention deficit hyperactivity disorder	1.44e-05	9.75e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.4e-05	9.49e-05	CbGpPWpGaD
Tolazoline—ADRA2B—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.29e-05	8.76e-05	CbGpPWpGaD
Tolazoline—ADRA2C—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.2e-05	8.18e-05	CbGpPWpGaD
Tolazoline—HRH2—Signaling Pathways—EP300—attention deficit hyperactivity disorder	1.16e-05	7.89e-05	CbGpPWpGaD
Tolazoline—HRH1—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.07e-05	7.29e-05	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.05e-05	7.15e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	9.79e-06	6.65e-05	CbGpPWpGaD
Tolazoline—ADRA2C—Metabolism—EP300—attention deficit hyperactivity disorder	7.63e-06	5.19e-05	CbGpPWpGaD
Tolazoline—ADRA2B—Signaling Pathways—EP300—attention deficit hyperactivity disorder	6.83e-06	4.64e-05	CbGpPWpGaD
Tolazoline—ADRA2C—Signaling Pathways—EP300—attention deficit hyperactivity disorder	6.38e-06	4.34e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Metabolism—EP300—attention deficit hyperactivity disorder	6.2e-06	4.21e-05	CbGpPWpGaD
Tolazoline—HRH1—Signaling Pathways—EP300—attention deficit hyperactivity disorder	5.69e-06	3.86e-05	CbGpPWpGaD
Tolazoline—ADRA1A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	5.58e-06	3.79e-05	CbGpPWpGaD
Tolazoline—ADRA2A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	5.19e-06	3.52e-05	CbGpPWpGaD
